Entrada Therapeutics (TRDA) news
Recent news
Entrada Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4)
AInvest Wire · Jun 1, 2026Entra summons written resolution to change bond terms
Entra ASA has issued a summons for a written resolution to amend the terms of its outstanding bonds, as outlined in a recent notice . The move follows standard procedures for altering bond agreements, which typically require approval from both the issuing entity and bondholders. Such modifications…
AInvest Wire · May 11, 2026ImportantEntrada Therapeutics Shares Tumble 29% After FDA Keeps Clinical Hold
AInvest Wire · Nov 22, 2023Entrada: FDA Declines to Lift Hold on Duchenne Study
Entrada Therapeutics on Wednesday said the U.S. Food and Drug Administration declined to lift the clinical hold on a planned study of ENTR-601-44 as a potential treatment of Duchenne muscular dystrophy.
AInvest Wire · Nov 22, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.